CymaBay Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CBAY research report →
About the company
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta.
- CEO
- Sujal A. Shah
- IPO
- 2014
- Employees
- 101
- HQ
- Newark, CA, US
Price Chart
- Market Cap
- $3.73B
- P/E
- -32.74
- P/S
- 119.98
- P/B
- 11.80
- EV/EBITDA
- -42.41
- Div Yield
- 0.00%
- Gross Margin
- 97.81%
- Op Margin
- -327.23%
- Net Margin
- -339.10%
- ROE
- -64.17%
- ROIC
- -24.93%
- Revenue
- $31.07M · 0.00%
- Net Income
- $-105,370,000 · 11.37%
- EPS
- $-0.99 · 26.67%
- Op Income
- $-101,679,000
- FCF YoY
- 13.36%
- 52W High
- $32.50
- 52W Low
- $7.26
- 50D MA
- $28.59
- 200D MA
- $18.42
- Beta
- 0.32
- Avg Volume
- 3.94M
Get TickerSpark's AI analysis on CBAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 22, 24 | Loewy Caroline M | sell | 32,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 30,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 15,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 7,500 |
| Mar 22, 24 | Loewy Caroline M | sell | 16,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 27,705 |
| Mar 22, 24 | Loewy Caroline M | sell | 49,245 |
| Mar 22, 24 | Loewy Caroline M | sell | 67,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 25,000 |
| Mar 22, 24 | Loewy Caroline M | sell | 14,010 |
Our CBAY coverage
Recent articles, reports, and earnings notes.
No research on CBAY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CBAY report →Similar companies
Peers in the same neighborhood.